Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
CJC-1295 (With DAC)
A GHRH analog with DAC modification studied for extended GH-release kinetics.
- Half-life (approx.)
- ~6–8 days (approx., subQ with DAC)
- Diluent
- Bacteriostatic water (0.9% benzyl alcohol)
- Common vials
- 2, 5 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
CJC-1295 with DAC (Drug Affinity Complex) extends half-life by albumin binding, producing sustained GHRH-receptor activation in endocrine studies. Compared to no-DAC forms, fewer injections are modeled in pharmacokinetic research — verify which variant your material matches. Albumin-binding DAC form — not interchangeable with Mod GRF 1-29 (no DAC) in research design.
Structure & identity
GHRH(1-29) + Drug Affinity Complex (Lys-CO-DAC)
- Sequence / structure
- GHRH(1-29) + Drug Affinity Complex (Lys-CO-DAC)
Mechanism
GHRH(1-29) analog with DAC binds albumin for extended GH-releasing activity. Extended GH-releasing activity from prolonged albumin association in subQ PK studies.
Studies & clinical programs
GH pulsatility profiling
Published research models
- Peer-reviewed literature documents endpoints under GH pulsatility profiling experimental designs.
Healthy volunteer PK studies
Published research models
- Peer-reviewed literature documents endpoints under Healthy volunteer PK studies experimental designs.
Research models in literature
- GH pulsatility profiling
- Healthy volunteer PK studies
Literature highlights
- Albumin-binding DAC extends GHRH(1-29) half-life in healthy-volunteer PK studies.
- GH pulsatility and IGF-1 elevation measured over multi-day sampling windows.
- Distinct from Mod GRF 1-29 (no DAC) — literature stresses non-interchangeable pharmacokinetics.
Combination research notes
Do not mix up with Mod GRF 1-29 (no DAC) — different half-life.
Key targets & pathways
Research areas
Routes in research literature
Also known as
Handling cautions
- Do not confuse with no-DAC Mod GRF 1-29
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Sealed vial, refrigerated (2–8 °C) | Intact lyophilized cake or powder is typically stable for months to years per published stability data; protect from moisture, light, and repeated freeze-thaw of the dry vial. |
| Reconstituted | Bacteriostatic water (0.9% benzyl alcohol), refrigerated | Most aqueous peptide solutions remain usable for approximately 2–4 weeks refrigerated; verify published stability data and label with reconstitution date. |
| Working aliquots | Pre-drawn syringes or microtubes, frozen (−20 °C) | Aliquot promptly after mixing to limit freeze-thaw cycles on the main vial; thaw once and use to reduce protease-mediated degradation. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 2 | 2 | 1000.0 | 10 | 25 | 50 |
| 5 | 2 | 2500.0 | 4 | 10 | 20 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Often reconstituted with 1–2 mL bacteriostatic water.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance